title: Peripheral neuropathy in ART-experienced patients: prevalence and risk factors.
abstract: Peripheral neuropathy (PN) is a common neurological complication of HIV infection that has debilitating effects on quality of life. While there has been a comprehensive evaluation of the prevalence of neuropathic signs/symptoms and risk factors (RFs) for PN or symptomatic PN (SPN) with initiation of combination antiretroviral therapy (cART) in ART-naïve patients, similar evaluation in ART-experienced patients is limited. This study investigated the prevalence and RFs for PN/SPN in ART-experienced patients enrolled in clinical salvage therapy studies. Between February 2000 and June 2007, 522 ART-experienced participants who experienced virologic failure with a prior regimen and started new regimens were followed longitudinally and annually screened for signs and symptoms of PN. Rates of PN/SPN at 3 years since parent study entry were 52.8 and 24.0 %, respectively. Aging, taller height, protease inhibitor use, and female sex were significant RFs for PN/SPN. The use of statin drugs was significantly associated with lower odds of SPN, and it may prevent progression from no SPN to SPN.
authors.affiliation: Harvard School of Public Health, 651 Huntington Avenue, FXB-607, Boston, MA, 02115, USA, hchen@sdac.harvard.edu.
authors.forename: Huichao
authors.initials: H
authors.lastname: Chen
authors.forename: David B
authors.initials: DB
authors.lastname: Clifford
authors.forename: Lijuan
authors.initials: L
authors.lastname: Deng
authors.forename: Kunling
authors.initials: K
authors.lastname: Wu
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Lee
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Bosch
authors.forename: Sharon A
authors.initials: SA
authors.lastname: Riddler
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Ellis
authors.forename: Scott R
authors.initials: SR
authors.lastname: Evans
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology* / Q000821:virology; D015497:HIV-1; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology* / Q000821:virology; D015995:Prevalence; D012307:Risk Factors; D012737:Sex Factors
chemical_list: D019380:Anti-HIV Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors